Rogerio S Gaspar

List of Publications by Year
in descending order

43 papers	5,020 citations	159525 30 h-index	289141 40 g-index
44 all docs	44 docs citations	44 times ranked	8060 citing authors

#	Article	IF	Citations
1	SARS-CoV-2 Variants and Vaccines. New England Journal of Medicine, 2021, 385, 179-186.	13.9	322
2	Considerations in boosting COVID-19 vaccine immune responses. Lancet, The, 2021, 398, 1377-1380.	6.3	267
3	Bridging communities in the field of nanomedicine. Regulatory Toxicology and Pharmacology, 2019, 106, 187-196.	1.3	32
4	Functional Moieties for Intracellular Traffic of Nanomaterials. , 2018, , 399-448.		4
5	Rational design of nanoparticles towards targeting antigen-presenting cells and improved T cell priming. Journal of Controlled Release, 2017, 258, 182-195.	4.8	79
6	Poly(lactic acid)-based particulate systems are promising tools for immune modulation. Acta Biomaterialia, 2017, 48, 41-57.	4.1	96
7	Regulatory Development of Nanotechnology-Based Vaccines. , 2017, , 393-410.		5
8	Current aspects of breast cancer therapy and diagnosis based on a nanocarrier approach. , 2017, , 749-774.		7
9	Liposomes as Delivery System of a Sn(IV) Complex for Cancer Therapy. Pharmaceutical Research, 2016, 33, 1351-1358.	1.7	18
10	Optimization of protein loaded PLGA nanoparticle manufacturing parameters following a quality-by-design approach. RSC Advances, 2016, 6, 104502-104512.	1.7	7
11	Modulation of Dendritic Cells by Nanotechnology-Based Immunotherapeutic Strategies. Journal of Biomedical Nanotechnology, 2016, 12, 405-434.	0.5	13
12	Regulatory aspects on nanomedicines. Biochemical and Biophysical Research Communications, 2015, 468, 504-510.	1.0	256
13	Translational Peptide-associated Nanosystems: Promising Role as Cancer Vaccines. Current Topics in Medicinal Chemistry, 2015, 16, 291-313.	1.0	2
14	Regulatory Aspects of Oncologicals: Nanosystems Main Challenges. Advances in Delivery Science and Technology, 2014, , 425-452.	0.4	14
15	Preclinical development of siRNA therapeutics: Towards the match between fundamental science and engineered systems. Nanomedicine: Nanotechnology, Biology, and Medicine, 2014, 10, 689-702.	1.7	48
16	How to Regulate Nonbiological Complex Drugs (NBCD) and Their Follow-on Versions: Points to Consider. AAPS Journal, 2014, 16, 15-21.	2.2	101
17	Cancer immunotherapy: nanodelivery approaches for immune cell targeting and tracking. Frontiers in Chemistry, 2014, 2, 105.	1.8	147
18	Pushed off target with proteins. Nature Nanotechnology, 2013, 8, 79-80.	15.6	45

#	Article	IF	Citations
19	Immune system targeting by biodegradable nanoparticles for cancer vaccines. Journal of Controlled Release, 2013, 168, 179-199.	4.8	212
20	Towards a European Strategy for Medicines Research (2014â€“2020): The EUFEPS Position Paper on Horizon 2020. European Journal of Pharmaceutical Sciences, 2012, 47, 979-987.	1.9	31
21	Nanomedicine(s) under the Microscope. Molecular Pharmaceutics, 2011, 8, 2101-2141.	2.3	815
22	Mesenchymal Stem Cells Promote Mammosphere Formation and Decrease E-Cadherin in Normal and Malignant Breast Cells. PLoS ONE, 2010, 5, e12180.	1.1	148
23	Polymeric carriers: Preclinical safety and the regulatory implications for design and development of polymer therapeutics. Advanced Drug Delivery Reviews, 2009, 61, 1220-1231.	6.6	254
24	Regulatory issues surrounding nanomedicines: setting the scene for the next generation of nanopharmaceuticals. Nanomedicine, 2007, 2, 143-147.	1.7	98
25	Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity. Journal of Controlled Release, 2002, 83, 273-286.	4.8	624
26	Use of the post-insertion technique to insert peptide ligands into pre-formed stealth liposomes with retention of binding activity and cytotoxicity. Pharmaceutical Research, 2002, 19, 265-269.	1.7	127
27	A growth factor antagonist as a targeting agent for sterically stabilized liposomes in human small cell lung cancer. Biochimica Et Biophysica Acta - Biomembranes, 2001, 1514, 303-317.	1.4	40
28	Targeting Stealth liposomes in a murine model of human small cell lung cancer. Biochimica Et Biophysica Acta - Biomembranes, 2001, 1515, 167-176.	1.4	88
29	Human serum albumin enhances DNA transfection by lipoplexes and confers resistance to inhibition by serum. Biochimica Et Biophysica Acta - Biomembranes, 2000, 1463, 459-469.	1.4	127
30	Mechanisms of gene transfer mediated by lipoplexes associated with targeting ligands or pH-sensitive peptides. Gene Therapy, 1999, 6, 1798-1807.	2.3	168
31	Successful Transfection of Lymphocytes by Ternary Lipoplexes. Bioscience Reports, 1999, 19, 601-609.	1.1	21
32	Interaction of cationic liposomes and their DNA complexes with monocytic leukemia cells. Biochimica Et Biophysica Acta - Biomembranes, 1999, 1418, 71-84.	1.4	111
33	Gene delivery mediated by cationic liposomes: from biophysical aspects to enhancement of transfection. Molecular Membrane Biology, 1999, 16, 103-109.	2.0	73
34	Transfection of human macrophages by lipoplexes via the combined use of transferrin and pH-sensitive peptides. Journal of Leukocyte Biology, 1999, 65, 270-279.	1.5	70
35	Gene delivery by negatively charged ternary complexes of DNA, cationic liposomes and transferrin or fusigenic peptides. Gene Therapy, 1998, 5, 955-964.	2.3	189
36	Interaction between polyalkylcyanoacrylate nanoparticles and peritoneal macrophages: MTT metabolism, NBT reduction, and NO production. Pharmaceutical Research, 1997, 14, 73-79.	1.7	46

#	Article	IF	Citations
37	An analytical methodology to quantify the incorporation of enzymes in polyalkylcyanoacrylate nanoparticles based on size exclusion chromatography. Journal of Pharmaceutical and Biomedical Analysis, 1997, 15, 811-818.	1.4	4
38	Steric stabilization of nanoparticles: Size and surface properties. International Journal of Pharmaceutics, 1996, 138, 1-12.	2.6	122
39	Enzyme-loaded PIBCA nanoparticles (SOD and l-ASNase): Optimization and characterization. International Journal of Pharmaceutics, 1996, 142, 75-84.	2.6	10
40	Development of enzyme-loaded nanoparticles: effect of pH. Journal of Materials Science: Materials in Medicine, 1996, 7, 413-414.	1.7	26
41	Drug targeting with polyalkylcyanoacrylate nanoparticles:in vitroactivity of primaquine-loaded nanoparticles against intracellularLeishmania donovani. Annals of Tropical Medicine and Parasitology, 1992, 86, 41-49.	1.6	65
42	Macrophage activation by polymeric nanoparticles of polyalkylcyanoacrylates: activity against intracellular Leishmania donovani associated with hydrogen peroxide production. Pharmaceutical Research, 1992, 09, 782-787.	1.7	56
43	Nanoparticles of polyisohexylcyanoaerylate (PIHCA) as carriers of primaquine: formulation, physico-chemical characterization and acute toxicity. International Journal of Pharmaceutics, 1991, 68, 111-119.	2.6	30